Reduction in cancer risk by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors

Area of Science:

• Oncology
• Pharmacology
• Epidemiology

Background:

• Overexpression of cyclooxygenase-2 (COX-2) and increased prostaglandin biosynthesis are linked to carcinogenesis and metastasis.
• Non-steroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors (coxibs) exhibit anti-cancer properties.

Purpose of the Study:

• To evaluate the chemopreventive effects of aspirin, ibuprofen, and coxibs against breast, colon, prostate, and lung cancers.
• To correlate the efficacy of these agents with their COX-2 selectivity.

Main Methods:

• Epidemiologic studies were conducted to assess cancer risk reduction.
• Analysis included regular intake of aspirin (325 mg), ibuprofen (200 mg), and coxibs (celecoxib 200 mg, rofecoxib 25 mg).
• Acetaminophen, lacking COX-2 activity, was used as a control.

Main Results:

• Regular intake of aspirin, ibuprofen, and coxibs showed risk reductions of 49%, 59%, and 64%, respectively.
• Long-term coxib use (≥2 years) demonstrated substantial risk reductions for breast (71%), colon (70%), prostate (55%), and lung (60%) cancers.
• Ibuprofen's effects were comparable to coxibs and superior to aspirin, aligning with their COX-2 selectivity. Acetaminophen showed no effect.

Conclusions:

• Regular use of nonselective and selective COX-2 inhibitors offers protection against major cancer types.
• The chemopreventive effects are consistent with the drugs' inhibition of the COX-2 pathway.
• Targeting COX-2 represents a viable strategy for cancer chemoprevention.